FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311914521> ?p ?o ?g. }

• W4311914521 endingPage "1902" @default.
• W4311914521 startingPage "1899" @default.
• W4311914521 abstract "HomeCirculationVol. 146, No. 25What Is the Future of Factor XI Inhibitors? No AccessArticle CommentaryRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessArticle CommentaryRequest AccessFull TextWhat Is the Future of Factor XI Inhibitors? Jeffrey I. Weitz and John W. Eikelboom Jeffrey I. WeitzJeffrey I. Weitz Correspondence to: Jeffrey Weitz, Thrombosis and Atherosclerosis Research Institute, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2. Email E-mail Address: [email protected] https://orcid.org/0000-0002-1092-7550 Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W., J.W.E.). Departments of Medicine (J.I.W., J.W.E.), McMaster University, Hamilton, Ontario, Canada. Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, Ontario, Canada. Search for more papers by this author and John W. EikelboomJohn W. Eikelboom https://orcid.org/0000-0003-4126-1285 Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W., J.W.E.). Departments of Medicine (J.I.W., J.W.E.), McMaster University, Hamilton, Ontario, Canada. Population Health Research Institute, Hamilton, Ontario, Canada (J.W.E.). Search for more papers by this author Originally published19 Dec 2022https://doi.org/10.1161/CIRCULATIONAHA.122.061132Circulation. 2022;146:1899–1902FootnotesCirculation is available at www.ahajournals.org/journal/circThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 1901.Correspondence to: Jeffrey Weitz, Thrombosis and Atherosclerosis Research Institute, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2. Email [email protected].caReferences1. Chan NC, Weitz JI. Antithrombotic agents.Circ Res. 2019; 124:426–436. doi: 10.1161/CIRCRESAHA.118.313155LinkGoogle Scholar2. Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence.Front Cardiovasc Med. 2022; 9:903029. doi: 10.3389/fcvm.2022.903029CrossrefMedlineGoogle Scholar3. Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, et al; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.Lancet. 2022; 399:1383–1390. doi: 10.1016/S0140-6736(22)00456-1CrossrefMedlineGoogle Scholar4. Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.Lancet. 2022; 400:997–1007. doi: 10.1016/S0140-6736(22)01588-4CrossrefMedlineGoogle Scholar5. Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xia inhibitor asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction.Circulation. 2022; 146:1196–1206. doi: 10.1161/CIRCULATIONAHA.122.061612LinkGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails December 20, 2022Vol 146, Issue 25 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.122.061132PMID: 36534732 Originally publishedDecember 19, 2022 Keywordsanticoagulantsfactor XIatrial fibrillationPDF download Advertisement" @default.
• W4311914521 created "2023-01-02" @default.
• W4311914521 creator A5082464840 @default.
• W4311914521 creator A5084746877 @default.
• W4311914521 date "2022-12-20" @default.
• W4311914521 modified "2023-09-29" @default.
• W4311914521 title "What Is the Future of Factor XI Inhibitors?" @default.
• W4311914521 cites W2912543621 @default.
• W4311914521 cites W4223439574 @default.
• W4311914521 cites W4280542721 @default.
• W4311914521 cites W4293410865 @default.
• W4311914521 cites W4296902187 @default.
• W4311914521 doi "https://doi.org/10.1161/circulationaha.122.061132" @default.
• W4311914521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36534732" @default.
• W4311914521 hasPublicationYear "2022" @default.
• W4311914521 type Work @default.
• W4311914521 citedByCount "3" @default.
• W4311914521 countsByYear W43119145212023 @default.
• W4311914521 crossrefType "journal-article" @default.
• W4311914521 hasAuthorship W4311914521A5082464840 @default.
• W4311914521 hasAuthorship W4311914521A5084746877 @default.
• W4311914521 hasConcept C161191863 @default.
• W4311914521 hasConcept C17744445 @default.
• W4311914521 hasConcept C199539241 @default.
• W4311914521 hasConcept C2779455604 @default.
• W4311914521 hasConcept C2908647359 @default.
• W4311914521 hasConcept C3019869117 @default.
• W4311914521 hasConcept C41008148 @default.
• W4311914521 hasConcept C71924100 @default.
• W4311914521 hasConcept C74916050 @default.
• W4311914521 hasConcept C95457728 @default.
• W4311914521 hasConcept C99454951 @default.
• W4311914521 hasConceptScore W4311914521C161191863 @default.
• W4311914521 hasConceptScore W4311914521C17744445 @default.
• W4311914521 hasConceptScore W4311914521C199539241 @default.
• W4311914521 hasConceptScore W4311914521C2779455604 @default.
• W4311914521 hasConceptScore W4311914521C2908647359 @default.
• W4311914521 hasConceptScore W4311914521C3019869117 @default.
• W4311914521 hasConceptScore W4311914521C41008148 @default.
• W4311914521 hasConceptScore W4311914521C71924100 @default.
• W4311914521 hasConceptScore W4311914521C74916050 @default.
• W4311914521 hasConceptScore W4311914521C95457728 @default.
• W4311914521 hasConceptScore W4311914521C99454951 @default.
• W4311914521 hasIssue "25" @default.
• W4311914521 hasLocation W43119145211 @default.
• W4311914521 hasLocation W43119145212 @default.
• W4311914521 hasOpenAccess W4311914521 @default.
• W4311914521 hasPrimaryLocation W43119145211 @default.
• W4311914521 hasRelatedWork W1547069466 @default.
• W4311914521 hasRelatedWork W2049569305 @default.
• W4311914521 hasRelatedWork W2240147207 @default.
• W4311914521 hasRelatedWork W2485306626 @default.
• W4311914521 hasRelatedWork W3013737583 @default.
• W4311914521 hasRelatedWork W3025857618 @default.
• W4311914521 hasRelatedWork W3112434114 @default.
• W4311914521 hasRelatedWork W3149981254 @default.
• W4311914521 hasRelatedWork W3194639136 @default.
• W4311914521 hasRelatedWork W2603421857 @default.
• W4311914521 hasVolume "146" @default.
• W4311914521 isParatext "false" @default.
• W4311914521 isRetracted "false" @default.
• W4311914521 workType "article" @default.